Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 26 Feb 2024 |
| Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally | 22 Feb 2024 |
| Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland | 19 Feb 2024 |
| Orion Group Financial Statement Release January-December 2023 | 13 Feb 2024 |
| Notice to the Annual General Meeting of Orion Corporation | 13 Feb 2024 |